Hepatitis C, chronic, combination therapy in interferon alfa-naïve patients with compensated liver disease. Respiratory syncytial virus infection.
Black Box Warning: Ribavirin monotherapy is ineffective for treatment of chronic hepatitis C virus infection. The primary toxicity is hemolytic anemia, which may result in worsening of cardiac disease and fatal and nonfatal myocardial infarctions. Avoid use in patients with significant or unstable cardiac disease. Ribavirin is contraindicated in women who are pregnant and in male partners of women who are pregnant. Use 2 reliable forms of contraception and avoid pregnancy during therapy and for 6 months after completion of treatment in both female patients and in female partners of male patients who are taking ribavirin.
Test CBC prior to initiating therapy, at weeks 2 and 4, more frequently if clinically warranted, and periodically thereafter.
Perform pregnancy test in women of childbearing potential prior to initiating treatment on a monthly basis during therapy and for 6 months after discontinuation.
Perform thyroid stimulating hormone test (TSH) prior to initiating therapy and periodically thereafter.
Perform renal function prior to initiation and periodically during therapy.
Perform eye exam at baseline in all patients and periodically during therapy.
Assess ECG in patients with preexisting heart disease prior to initiating therapy and periodically thereafter.
Common
Severe
Contraindications:
Drug-drug interactions:
Antimicrobial class: Antiviral agent, Guanosine nucleoside analog, Viral RNA polymerase inhibitor
Pregnancy category: Contraindicated; do NOT use in pregnancy
Average serum half life: 298 hours (oral), 9.5 hours (inhalation)
Precautions:
항생제
